Simultaneous isocratic HPLC determination of vigabatrin and gabapentin in human plasma by dansyl derivatization

Therapeutic Drug Monitoring

Volumn 25, Issue 3, 2003, Pages 374-377

  Krivanek, Peter ^a   Koppatz, Karl ^a   Turnheim, Klaus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dansyl chloride; Gabapentin; High performance liquid chromatography (HPLC); Therapeutic drug monitoring (TDM); Vigabatrin

Indexed keywords

ACETONITRILE; DANSYL CHLORIDE; GABAPENTIN; VIGABATRIN;

ARTICLE; CALIBRATION; CORRELATION COEFFICIENT; COST; DERIVATIZATION; DRUG DETERMINATION; DRUG MONITORING; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PATIENT COMPLIANCE; PLASMA; PRIORITY JOURNAL;

EID: 0038103479     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200306000-00019     Document Type: Article

References (21)

1. Gidal BE, Privitera MD, Sheth RD et al. Vigabatrin: a novel therapy for seizure disorders. Ann Pharmacother 1999;33:1277-86.
2. McLean MJ. Gabapentin in the management of convulsive disorders. Epilepsia 1999;6:S39-50.
3. Sabers A, Grams L. Pharmacology of vigabatrin. Pharmacol Toxicol 1992;70:237-43.
4. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001;15:339-50.
5. Taylor C. Emerging perspective on the mechanism of action of gabapentin. Neurology 1994;44(suppl 5):S10-6.
6. Alden KJ, Garcia J. Differential effect of gabapentin on neuronal and muscle calcium currents. J Pharmacol Exp Ther 2001;297:727-35.
7. Tsanaclis LM, Wicks J, Williams J, et al. Determination of vigabatrin in plasma by reversed phase high performance liquid chromatography. Ther Drug Monit 1991;13:251-3.
8. Erturk S, Aktas ES, Atmaca S. Determination of vigabatrin in human plasma and urine by high performance liquid chromatography with fluorescence detection. J Chromatogr B 2001;760:207-12.
9. Lensmeyer GL, Kempf T, Gidal BE, et al. Optimized method for the determination of gabapentin in serum by high pressure liquid chromatography. Ther Drug Monit 1995;17:251-8.
10. Forrest G, Sills GJ, Leach JP, et al. Determination of gabapentin by high performance liquid chromatography. J Chromatogr B 1996;681:421-5.
11. Tang PH, Miles MV, Glauser TA, et al. Automated microanalysis of gabapentin in human serum by high performance liquid chromatography with fluorometric detection. J Chromatogr B 1999;727:125-9.
12. Juergens UH, May TW, Rambeck B. Simultaneous HPLC determination of vigabatrin and gabapentin in serum with automated pre-injection derivatization. J Chromatogr Rel Techn 1996;19:1459-71.
13. Ratnaraj N, Patsalos PN. A high performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin. Ther Drug Monit 1998;20:430-4.
14. Wad N, Kraemer G. Sensitive high performance liquid chromatographic method with fluorometric detection for the simultaneous determination of gabapentin and vigabatrin in serum and urine. J Chromatogr B 1998;705:154-8.
15. Chollet DF, Goumaz L, Juliano C, et al. Fast high performance liquid chromatographic assay method for the simultaneous determination of gabapentin and vigabatrin in human serum. J Chromatogr B 2000;746:311-4.
16. Gray WR. End group analysis using dansyl chloride. In: Hirs CHW, Timashef SN, eds. Methods in enzymology, vol, XXV. New York and London: Academic Press, 1972:121-30.
17. Eadie MJ. Therapeutic drug monitoring - antiepileptic drugs. Br J Pharmacol 1998;46:185-93.
18. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: examining its role in the treatment of epilepsy. Epilepsia 2000;41(suppl 8):S6-15.
19. Schumacher GE, Barr JT. Therapeutic drug monitoring: do the improved outcomes justify the costs? Clin Pharmacokinet 2001;40:405-9.
20. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmakol 2000;55:697-705.
21. Patsalos PN. New antiepileptic drugs. Ann Clin Biochem 1999;36:10-9.